In Vivo Synaptic Density Imaging with ¹¹C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease.

ABSTRACT: ¹¹C-UCB-J is a new PET tracer for synaptic density imaging. Recently, we conducted ¹¹C-UCB-J PET on patients with mild cognitive impairment or early Alzheimer disease (AD) and found a 41% decrease in specific binding in the hippocampus compared with healthy subjects. We hypothesized that ¹¹C-UCB-J may have potential to be a general biomarker for evaluating AD treatment effects via monitoring of synaptic density changes. In this study, we performed longitudinal ¹¹C-UCB-J PET on AD mice to measure the treatment effects of saracatinib, which previously demonstrated synaptic changes with postmortem methods. Methods: Nine wild-type (WT) mice and 9 amyloid precursor protein and presenilin 1 double-transgenic (APPswe/PS1ΔE9 [APP/PS1]) mice underw

SUBMITTER: Toyonaga T 

PROVIDER: S-EPMC6894376 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature